Overview

Abraxane in Treatment of Metastatic Breast Cancer

Status:
Completed
Trial end date:
2016-12-31
Target enrollment:
Participant gender:
Summary
This observational project is collecting tolerability, safety and efficacy data with the routine use of Abraxane in the treatment of metastatic breast cancer. Additionally data on the dosage of Abraxane and general data on the disease and the health status of the patient will be collected.
Details
Lead Sponsor:
Celgene
Celgene Corporation
Treatments:
Albumin-Bound Paclitaxel
Paclitaxel